Top Markets
Coin of the day
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCIF
Rang in aandelen #99999
Intellipharmaceutics International Inc., a pharmaceutical company, researches,... Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
Aandeelprijs
$0.15
Marktkapitalisatie
$4.96M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
CA
Handel Intellipharmaceutics International Inc. (IPCIF)

Categorie

Operationele marge voor Intellipharmaceutics International Inc. (IPCIF)
Operationele marge op March 2026 TTM: -4,336.82%
Volgens de meest recente financiële rapporten en aandelenkoers van Intellipharmaceutics International Inc. is de huidige operationele marge (TTM) -4,336.82%. Eind 2021 had het bedrijf een operationele marge van -4,336.82%.
Geschiedenis van de operationele marge van Intellipharmaceutics International Inc. van 1999 tot 2026
Operationele marge aan het einde van elk jaar
Jaar Operationele Marge Wijzigen
2026 (TTM) -4,336.82% 0.00%
2022 -4,336.82% 0.00%
2021 -4,336.82% 1,356.53%
2020 -297.75% -10.80%
2019 -333.80% -57.10%
2018 -778.07% 418.13%
2017 -150.17% -65.75%
2016 -438.41% 152.31%
2015 -173.76% 331.38%
2014 -40.28% -90.98%
2013 -446.40% -95.27%
2012 -9,447.17% 509.60%
2011 -1,549.72% 273.68%
2010 -414.72% 0.00%
2009 0.00% 0.00%
2008 0.00% 0.00%
2007 0.00% 0.00%
2006 0.00% 0.00%
2005 0.00% 0.00%
2004 0.00% 0.00%
2003 0.00% 0.00%
2002 0.00% -100.00%
2001 -1,046,045.90% 42.56%
2000 -733,774.14% 13,744.82%
1999 -5,299.99% 0.00%
Operationele marge van vergelijkbare bedrijven of concurrenten
Bedrijf Operationele Marge Verschil in operationele marge Land
41.30% -100.01%
DK
35.45% -100.01%
US
24.95% -100.01%
US
25.32% -100.01%
BE
25.64% -100.01%
NL
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.